Drug-class toxicities of BRAF inhibitors encompass pyrexia, arthralgia, fatigue, headache, cutaneous toxicities and growth of secondary skin neoplasms like cutaneous squamous-cell carcinoma palmoplantar erythrodysesthesia gastrointestinal side effects and elevated serum transaminases (Table 3) (78, 79). The gene discussed is BRAF; the disease is skin neoplasm.